Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacoeconomic considerations.

Bob L Lobo1

  • 1Methodist Healthcare University Hospital, Memphis, USA. lobob@methodisthealth.org

American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|December 4, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Role of Computerized Clinical Decision Support in Reducing Inappropriate Medication Administration During Epidural Therapy.

Hospital pharmacy·2018
Same author

Acute care clinical pharmacy practice: unit- versus service-based models.

Pharmacotherapy·2012
Same author

Risk of venous thromboembolism in hospitalized patients with peripherally inserted central catheters.

Journal of hospital medicine·2009
Same author

Evaluation of glycemic control following discontinuation of an intensive insulin protocol.

Journal of hospital medicine·2009
Same author

Heparin-induced thrombocytopenia complicated by warfarin-induced skin necrosis.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2008
Same author

Blood pressure management in acute hypertensive emergency.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2007
Same journal

Implementation of a paid apprenticeship-model pharmacy technician training program.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Iodixanol-induced acute generalized exanthematous pustulosis: Cross-reactivity to other iodinated contrast media.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Sonrotoclax.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Bulevirtide Acetate-gmod.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Addressing feedback overload in pharmacy residents.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Development of a psychiatric pharmacy internship program at a children's hospital.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
See all related articles

Pharmacoeconomic analysis shows fondaparinux is cost-effective for preventing venous thromboembolism (VTE) after orthopedic surgery. This factor Xa inhibitor reduces VTE events and associated healthcare costs compared to enoxaparin.

Area of Science:

  • Orthopedic Surgery
  • Pharmacoeconomics
  • Vascular Medicine

Background:

  • Venous thromboembolism (VTE) poses significant morbidity and mortality risks post-orthopedic surgery.
  • The economic burden of VTE includes extended hospital stays, ICU utilization, and increased overall costs.
  • Effective VTE prophylaxis is crucial to mitigate these adverse outcomes and financial impacts.

Purpose of the Study:

  • To evaluate the cost-effectiveness of fondaparinux versus enoxaparin for VTE prophylaxis in orthopedic surgery patients.
  • To analyze the economic impact of VTE and the benefits of effective prevention strategies.
  • To compare a 7-day regimen of fondaparinux (2.5 mg daily) with enoxaparin (30 mg twice daily).

Main Methods:

  • Utilized trial-based and effectiveness-based pharmacoeconomic analyses.

Related Experiment Videos

  • Compared fondaparinux and enoxaparin for VTE prophylaxis in the orthopedic postsurgical setting.
  • Assessed cost-effectiveness over various time points: discharge, 30 days, 3 months, and 5 years postdischarge.

    • Main Results:

    • Fondaparinux demonstrated superior VTE event prevention compared to enoxaparin in both analyses.
    • Trial-based analysis: Fondaparinux prevented 15.1 VTE events per 1000 patients at 3 months.
    • Effectiveness-based analysis: Fondaparinux prevented 17.7 VTE events per 1000 patients at 3 months.
    • Fondaparinux yielded cost savings per patient across multiple follow-up periods.

    Conclusions:

    • Fondaparinux is a cost-effective option for VTE prophylaxis in the orthopedic postsurgical population.
    • Implementing fondaparinux can lead to significant healthcare cost reductions by preventing VTE events and complications.
    • Pharmacoeconomic evaluations are valuable tools for optimizing VTE management strategies in surgical settings.